<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03968445</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-300003221 R19-045</org_study_id>
    <nct_id>NCT03968445</nct_id>
  </id_info>
  <brief_title>Neuroinflammation After Myocardial Infarction - Imaging Substudy</brief_title>
  <official_title>Neuroinflammation After Myocardial Infarction - Imaging Substudy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to see if positron emission tomography and magnetic resonance&#xD;
      imaging (PET/MRI) with an investigational drug called [18F]DPA-714 will show inflammation in&#xD;
      the brain after a heart attack. This study may help physicians and researchers better&#xD;
      understand the role of brain inflammation in heart disease and develop new treatments to&#xD;
      protect the brain.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to measure the concentration and the regional brain&#xD;
      distribution of activated brain microglia/macrophages using the PET ligand [18F]DPA-714 in&#xD;
      individuals with recent AMI. The basic premise is that AMI leads to systemic inflammation&#xD;
      that includes inflammation in the brain. The PET tracer [18F]DPA-714 binds to the 18 kDa&#xD;
      translocator protein (TSPO, also known as the peripheral benzodiazepine receptor) in the&#xD;
      mitochondria of activated microglia/macrophages and provides a non-invasive measure of&#xD;
      neuroinflammation. The estimates of brain TSPO binding in patients with recent AMI will be&#xD;
      compared to a matched group of patients who have undergone a recent elective PCI procedure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 17, 2019</start_date>
  <completion_date type="Anticipated">July 24, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 24, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TPSO-PET measurement of neuroinflammation after acute myocardial infarction</measure>
    <time_frame>2 years</time_frame>
    <description>The regional brain concentrations of [F-18]DPA-714, a PET imaging marker of neuroinflammation, will be compared between study participants who have recently been hospitalized for acute myocardial infarction (AMI) and a control group undergoing elective percutaneous coronary interventions (PCI).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Recent Myocardial Infarction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>undergoing elective percutaneous coronary intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F]DPA-714-PET/MRI</intervention_name>
    <description>[18F]DPA-714-PET/MRI</description>
    <arm_group_label>Recent Myocardial Infarction</arm_group_label>
    <arm_group_label>undergoing elective percutaneous coronary intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participation in UAB IRB protocol &quot;Neuroinflammation After Acute Myocardial&#xD;
             Infarction&quot; (IRB-300002751, PI Lazar).&#xD;
&#xD;
          2. 21 years of age or older&#xD;
&#xD;
          3. . English speaking with at least 8th grade education&#xD;
&#xD;
          4. High or mixed affinity binder for TSPO ligands based on genotyping for single&#xD;
             nucleotide polymorphism (SNP) rs6971.&#xD;
&#xD;
          5. Admission to UAB Hospital for ST-elevation acute myocardial infarction (AMI) and&#xD;
             treatment with percutaneous coronary intervention (PCI) OR Undergoing elective&#xD;
             percutaneous coronary intervention (PCI)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Contraindication to MRI&#xD;
&#xD;
          2. Pregnancy&#xD;
&#xD;
          3. Lactation&#xD;
&#xD;
          4. Serious medical co-morbidity that may interfere with participation&#xD;
&#xD;
          5. Prior myocardial infarction&#xD;
&#xD;
          6. Severe anemia&#xD;
&#xD;
          7. Prior coronary artery bypass grafting&#xD;
&#xD;
          8. Prior angioplasty and/or coronary artery stent placement (PCI group only)&#xD;
&#xD;
          9. History of traumatic head injury defined by a loss of consciousness â‰¥30 minutes or&#xD;
             seizure at the time of injury&#xD;
&#xD;
         10. Diagnosis of major depression&#xD;
&#xD;
         11. Diagnosis of dementia&#xD;
&#xD;
         12. Low affinity binder for TSPO ligands based on genotyping for SNP rs6971.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jonathan McConathy, MD, PhD</last_name>
    <phone>205-996-7115</phone>
    <email>jmcconathy@uabmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>April Riddle, BS RT</last_name>
    <phone>205-934-6504</phone>
    <email>ariddle@uabmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham Medical Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan McConathy, MD</last_name>
      <phone>205-996-7115</phone>
      <email>jmcconathy@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan McConathy, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bag Asim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bhambhvani Pradeep, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Choudhary Gagandeep, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Geldmacher David, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lapi Suzanne, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeffers Charlotte Denise, RPh</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Natelson Marissa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roberson Erik, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 16, 2019</study_first_submitted>
  <study_first_submitted_qc>May 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2019</study_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Jonathan E McConathy</investigator_full_name>
    <investigator_title>M.D. P.h.D., Director for the Division Molecular Imaging and Therapeutics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

